Skip to main content

Adamis Pharmaceuticals Value Stock - Dividend - Research Selection

Adamis Pharmaceuticals

ISIN: US00547W2089, WKN: A1XA2F

Market price date: 25.09.2020
Market price: 0,72 USD




Adamis Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 10-09-2020
Cash flow
Net operating cash flow -19.885.700
Capital Expenditures -2.866.420
Free cash flow -22.752.120
Balance sheet
Total Equity 36.037.200
Liabilities & Shareholders equity 47.840.500
Income statement
Net income -29.306.800
Eps (diluted) -0,550
Diluted shares outstanding 53.285.100
Net sales/revenue 22.113.900

Fundamental ratios calculated on: 25-09-2020

Ratios
Key figures 25-09-2020
Cash flow
P/C -1,93
   
P/FC -1,69
Balance sheet
ROI-61,26
ROE75,33
Income statement
P/E-1,31
Div. Yield0,00%
P/B1,07
P/S1,74


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolADMP
Market Capitalization38.365.272,00 USD
CountryUnited States
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split2013-12-13,1.000000/17.000000; 2009-04-22,296.000000/2939.000000
Internethttp://www.adamispharmaceuticals.com


Description of the company

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, http://www.adamispharmaceuticals.com